Drug development is a costly process and mistakes and misjudgements can be expensive. Engaging with experienced statisticians throughout the development process can bring a multitude of benefits to organisations, including designing more efficient trials and conducting and interpreting effective data analyses. This can result in a positive impact on your overall strategy, critical decision making and communication that is recognised by the MHRA and other regulatory agencies.
The External Affairs (EA) committee at PSI aims to promote statistical insight and rigour within the pharmaceutical industry. One of the ways the EA committee do this is through their webinar, “The importance of good statistical practice in drug development,” which is now available to download from the PSI website. The webinar, which lasts approximately 30 minutes, shares with you real life examples that show how:
- Statisticians offer unique strategic and analytic skills to provide support throughout the drug development process
- Statisticians can assist in shaping efficient development programmes and working with Regulatory Agencies
- Statisticians can offer innovative design options that help make the right decisions at the right time for the right cost
Please take a look at the webinar and feel free to contact the EA committee via PSI@mci-group.com if you have any questions.
Many thanks,
The PSI External Affairs Committee.